CA2905457A1 - Treatment of cataplexy - Google Patents
Treatment of cataplexy Download PDFInfo
- Publication number
- CA2905457A1 CA2905457A1 CA2905457A CA2905457A CA2905457A1 CA 2905457 A1 CA2905457 A1 CA 2905457A1 CA 2905457 A CA2905457 A CA 2905457A CA 2905457 A CA2905457 A CA 2905457A CA 2905457 A1 CA2905457 A1 CA 2905457A1
- Authority
- CA
- Canada
- Prior art keywords
- formula
- enantiomer
- compound
- cataplexy
- predominates
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/02—Halogenated hydrocarbons
- A61K31/025—Halogenated hydrocarbons carbocyclic
- A61K31/03—Halogenated hydrocarbons carbocyclic aromatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/02—Carbamic acids; Salts of carbamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Anesthesiology (AREA)
- Psychology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361778998P | 2013-03-13 | 2013-03-13 | |
| US61/778,998 | 2013-03-13 | ||
| PCT/US2014/023969 WO2014164969A1 (en) | 2013-03-13 | 2014-03-12 | Treatment of cataplexy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2905457A1 true CA2905457A1 (en) | 2014-10-09 |
Family
ID=51530017
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2905457A Abandoned CA2905457A1 (en) | 2013-03-13 | 2014-03-12 | Treatment of cataplexy |
Country Status (21)
| Country | Link |
|---|---|
| US (7) | US9359290B2 (OSRAM) |
| EP (1) | EP2968208B1 (OSRAM) |
| JP (2) | JP6530741B2 (OSRAM) |
| KR (1) | KR102192554B1 (OSRAM) |
| CN (1) | CN105431142B (OSRAM) |
| AU (1) | AU2014248849B2 (OSRAM) |
| BR (1) | BR112015022197B1 (OSRAM) |
| CA (1) | CA2905457A1 (OSRAM) |
| DK (1) | DK2968208T3 (OSRAM) |
| ES (1) | ES2927675T3 (OSRAM) |
| HR (1) | HRP20221018T1 (OSRAM) |
| HU (1) | HUE060060T2 (OSRAM) |
| MX (1) | MX381381B (OSRAM) |
| MY (1) | MY177740A (OSRAM) |
| PH (1) | PH12015502075A1 (OSRAM) |
| PT (1) | PT2968208T (OSRAM) |
| RU (2) | RU2689984C2 (OSRAM) |
| SG (1) | SG11201507121RA (OSRAM) |
| SI (1) | SI2968208T1 (OSRAM) |
| TW (2) | TWI663971B (OSRAM) |
| WO (1) | WO2014164969A1 (OSRAM) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2417077C2 (ru) * | 2005-06-08 | 2011-04-27 | Ск Холдингз Ко., Лтд. | Способ лечения чрезмерной дневной сонливости (варианты) |
| KR102173587B1 (ko) | 2009-06-22 | 2020-11-04 | 에스케이바이오팜 주식회사 | 피로의 치료 또는 예방 방법 |
| SG11201507121RA (en) * | 2013-03-13 | 2015-10-29 | Aerial Biopharma Llc | Treatment of cataplexy |
| CA2917702A1 (en) | 2013-07-18 | 2015-01-22 | Jazz Pharmaceuticals International Iii Limited | Treatment for obesity |
| US11504347B1 (en) | 2016-07-22 | 2022-11-22 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12186296B1 (en) | 2016-07-22 | 2025-01-07 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12478604B1 (en) | 2016-07-22 | 2025-11-25 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11602513B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| UY37341A (es) | 2016-07-22 | 2017-11-30 | Flamel Ireland Ltd | Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada |
| US11986451B1 (en) | 2016-07-22 | 2024-05-21 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11602512B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US10195151B2 (en) | 2016-09-06 | 2019-02-05 | Jazz Pharmaceuticals International Iii Limited | Formulations of (R)-2-amino-3-phenylpropyl carbamate |
| CN109996540A (zh) | 2016-09-06 | 2019-07-09 | 爵士制药国际Iii有限公司 | (r)-2-氨基-3-苯丙基氨基甲酸酯的溶剂化物形式 |
| JP7074750B2 (ja) | 2016-10-06 | 2022-05-24 | ジャズ ファーマスティカルズ アイルランド リミテッド | カルバモイルフェニルアラニノール化合物およびその使用 |
| MY203401A (en) | 2017-06-02 | 2024-06-26 | Jazz Pharmaceuticals Ireland Ltd | Methods and compositions for treating excessive sleepiness |
| CN111094238B (zh) | 2017-07-31 | 2023-06-09 | 杰资制药爱尔兰有限公司 | 氨基甲酰基苯丙氨醇类似物及其用途 |
| MX2020002741A (es) * | 2017-09-12 | 2020-07-21 | Ovid Therapeutics Inc | Uso de gaboxadol en el tratamiento de narcolepsia. |
| CN111867573A (zh) | 2018-01-29 | 2020-10-30 | 科诺斯治疗学公司 | 硼替佐米的瘤内递送 |
| US20190381056A1 (en) | 2018-06-17 | 2019-12-19 | Axsome Therapeutics, Inc. | Compositions for delivery of reboxetine |
| SG11202103588WA (en) * | 2018-10-15 | 2021-05-28 | Axsome Therapeutics Inc | Use of reboxetine to treat narcolepsy |
| US20200147093A1 (en) | 2018-10-15 | 2020-05-14 | Axsome Therapeutics, Inc. | Use of esreboxetine to treat nervous system disorders such as fibromyalgia |
| US11020402B2 (en) | 2018-10-15 | 2021-06-01 | Axsome Therapeutics, Inc. | Use of reboxetine to treat narcolepsy |
| WO2021113163A1 (en) * | 2019-12-03 | 2021-06-10 | Axsome Therapeutics, Inc. | Use of reboxetine to treat nervous system disorders |
| EP3930702A1 (en) | 2019-03-01 | 2022-01-05 | Flamel Ireland Limited | Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state |
| MX2022006630A (es) * | 2019-12-03 | 2022-06-24 | Axsome Therapeutics Inc | Uso de reboxetina para tratar los trastornos del sistema nervioso. |
| TW202139986A (zh) | 2020-02-21 | 2021-11-01 | 愛爾蘭商爵士製藥愛爾蘭有限責任公司 | 治療原發性嗜睡症之方法 |
| US10940133B1 (en) | 2020-03-19 | 2021-03-09 | Jazz Pharmaceuticals Ireland Limited | Methods of providing solriamfetol therapy to subjects with impaired renal function |
| KR102390194B1 (ko) * | 2020-08-03 | 2022-04-25 | 셀라이온바이오메드 주식회사 | 페닐알킬 카바메이트 화합물을 포함하는 Kca3.1채널 매개질환 치료용 조성물 |
| US11583510B1 (en) | 2022-02-07 | 2023-02-21 | Flamel Ireland Limited | Methods of administering gamma hydroxybutyrate formulations after a high-fat meal |
| US11779557B1 (en) | 2022-02-07 | 2023-10-10 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| WO2025006965A1 (en) | 2023-06-29 | 2025-01-02 | Axsome Therapeutics, Inc. | Methods of administering solriamfetol to lactating women |
| WO2025042959A1 (en) * | 2023-08-21 | 2025-02-27 | Axsome Therapeutics, Inc. | Use of solriamfetol for the treatment of orphan diseases |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US178429A (en) * | 1876-06-06 | Improvement in hulling-machines | ||
| CZ285762B6 (cs) | 1993-06-10 | 1999-11-17 | Eli Lilly And Company | Farmaceutický prostředek vhodný pro prevenci dávení a zvracení a pro ošetřování sexuální dysfunkce savců a jeho použití |
| KR100197892B1 (ko) | 1994-09-09 | 1999-06-15 | 남창우 | 신규한 페닐알킬아미노 카바메이트 화합물과 그의 제조방법 |
| KR0173862B1 (ko) | 1995-02-11 | 1999-04-01 | 조규향 | O-카바모일-(d)-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법 |
| US5756817C1 (en) | 1995-02-11 | 2001-04-17 | Sk Corp | O-carbamoyl-phenylananinol compounds their pharmaceutically useful salts and process for preparing the same |
| KR0173863B1 (ko) | 1995-04-10 | 1999-04-01 | 조규향 | 페닐에 치환체가 있는 o-카바모일-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법 |
| DK0873308T3 (da) | 1996-10-10 | 2002-04-22 | Sk Corp | O-Carbamoyl-phenylalaninol-forbindelser og deres farmaceutisk anvendelige salte |
| AU4674797A (en) | 1996-10-22 | 1998-05-15 | Ortho Pharmaceutical Corporation | Phenylalaninol derivatives for the treatment of central nervous system disorders |
| US6204245B1 (en) * | 1999-09-17 | 2001-03-20 | The Regents Of The University Of California | Treatment of narcolepsy with immunosuppressants |
| US20030207857A1 (en) | 2001-04-11 | 2003-11-06 | Adam Mavis D. | Phenyl heterocyclyl ethers |
| GB0109103D0 (en) * | 2001-04-11 | 2001-05-30 | Pfizer Ltd | Novel compounds |
| US20050080268A1 (en) | 2003-10-08 | 2005-04-14 | Yong-Moon Choi | Process of preparing O-carbamoyl compounds in the presence of active amine group |
| JP2007531755A (ja) * | 2004-03-31 | 2007-11-08 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 非イミダゾール系複素環式化合物 |
| EP1786437A4 (en) * | 2004-09-07 | 2010-12-08 | Orphan Medical Inc | IMPROVED GHB COMPOSITIONS |
| BRPI0518233A2 (pt) | 2004-10-28 | 2008-11-11 | Sk Corp | terapia adjunta para depressço |
| RU2417077C2 (ru) * | 2005-06-08 | 2011-04-27 | Ск Холдингз Ко., Лтд. | Способ лечения чрезмерной дневной сонливости (варианты) |
| ATE459393T1 (de) | 2005-06-22 | 2010-03-15 | Sk Holdings Co Ltd | Behandlung der sexuellen dysfunktion |
| ES2385087T3 (es) | 2005-07-26 | 2012-07-18 | Sk Biopharmaceuticals Co., Ltd | Procedimientos para tratar trastornos relacionados con sustancias |
| FR2903904A1 (fr) * | 2006-07-21 | 2008-01-25 | Bioprojet Soc Civ Ile | Association de modafinil et d'un antagoniste ou agoniste inverse du recepteur h3 |
| AU2007313017A1 (en) | 2006-10-13 | 2008-04-24 | Janssen Pharmaceutica, N.V. | Phenylalkylamino carbamate compositions |
| EP2078037A4 (en) * | 2006-11-10 | 2010-01-27 | Dimerix Bioscience Pty Ltd | HETERODIMERS / OLIGOMERS OF THE RECEPTOR FOR THE THYROTROPIN RELEASING HORMONE OF THE OREXIN RECEPTOR |
| KR102173587B1 (ko) * | 2009-06-22 | 2020-11-04 | 에스케이바이오팜 주식회사 | 피로의 치료 또는 예방 방법 |
| US8232315B2 (en) | 2009-06-26 | 2012-07-31 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating drug addiction and improving addiction-related behavior |
| AU2010316106B2 (en) | 2009-11-06 | 2015-10-22 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating attention-deficit/hyperactivity disorder |
| CA2779442A1 (en) | 2009-11-06 | 2011-05-12 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating fibromyalgia syndrome |
| US8623913B2 (en) | 2010-06-30 | 2014-01-07 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating restless legs syndrome |
| US9610274B2 (en) | 2010-06-30 | 2017-04-04 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating bipolar disorder |
| SG11201507121RA (en) * | 2013-03-13 | 2015-10-29 | Aerial Biopharma Llc | Treatment of cataplexy |
-
2014
- 2014-03-12 SG SG11201507121RA patent/SG11201507121RA/en unknown
- 2014-03-12 AU AU2014248849A patent/AU2014248849B2/en active Active
- 2014-03-12 JP JP2016501395A patent/JP6530741B2/ja active Active
- 2014-03-12 PT PT147780886T patent/PT2968208T/pt unknown
- 2014-03-12 ES ES14778088T patent/ES2927675T3/es active Active
- 2014-03-12 CN CN201480027152.9A patent/CN105431142B/zh active Active
- 2014-03-12 RU RU2015143610A patent/RU2689984C2/ru active
- 2014-03-12 TW TW103108612A patent/TWI663971B/zh active
- 2014-03-12 SI SI201431991T patent/SI2968208T1/sl unknown
- 2014-03-12 DK DK14778088.6T patent/DK2968208T3/da active
- 2014-03-12 KR KR1020157027978A patent/KR102192554B1/ko active Active
- 2014-03-12 CA CA2905457A patent/CA2905457A1/en not_active Abandoned
- 2014-03-12 MX MX2015012644A patent/MX381381B/es unknown
- 2014-03-12 HR HRP20221018TT patent/HRP20221018T1/hr unknown
- 2014-03-12 MY MYPI2015703166A patent/MY177740A/en unknown
- 2014-03-12 HU HUE14778088A patent/HUE060060T2/hu unknown
- 2014-03-12 EP EP14778088.6A patent/EP2968208B1/en active Active
- 2014-03-12 US US14/205,423 patent/US9359290B2/en active Active
- 2014-03-12 BR BR112015022197-1A patent/BR112015022197B1/pt active IP Right Grant
- 2014-03-12 RU RU2019114940A patent/RU2019114940A/ru not_active Application Discontinuation
- 2014-03-12 WO PCT/US2014/023969 patent/WO2014164969A1/en not_active Ceased
- 2014-03-12 TW TW108107074A patent/TWI684450B/zh active
-
2015
- 2015-09-11 PH PH12015502075A patent/PH12015502075A1/en unknown
-
2016
- 2016-05-09 US US15/149,478 patent/US9585863B2/en active Active
-
2017
- 2017-01-30 US US15/419,133 patent/US10259780B2/en active Active
-
2019
- 2019-03-20 US US16/359,446 patent/US11072579B2/en active Active
- 2019-05-17 JP JP2019093823A patent/JP2019147830A/ja active Pending
-
2021
- 2021-07-23 US US17/383,707 patent/US11713292B2/en active Active
-
2023
- 2023-06-19 US US18/337,299 patent/US12162821B2/en active Active
-
2024
- 2024-11-04 US US18/935,803 patent/US20250059135A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12162821B2 (en) | Treatment of cataplexy | |
| CA2801243C (en) | Methods of treating restless legs syndrome | |
| US9688620B2 (en) | Methods for treating fibromyalgia syndrome | |
| AU2011272156B2 (en) | Methods for treating bipolar disorder | |
| CA2917702A1 (en) | Treatment for obesity | |
| HK1178796B (en) | Methods of treating restless legs syndrome |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20190213 |
|
| FZDE | Discontinued |
Effective date: 20210831 |